Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Prebet

Showing results (21-30 of 99) with videos related to

Pageof 10
Sort By:
Journal of Hematology & Oncology|October 27, 2022
Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, phase 3 trialJorge E Cortes, Tara L Lin, Kobby Asubonteng, et al.
Frontiers in Immunology|April 10, 2014
Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor ActivityAnne-Sophie Chretien, Aude Le Roy, Norbert Vey, et al.
Blood Advances|February 16, 2021
Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemiaKishan K Patel, Amer M Zeidan, Rory M Shallis, et al.
Leukemia Research|December 22, 2007
Common features of myeloproliferative disorders with t(8;9)(p12;q33) and CEP110-FGFR1 fusion: report of a new case and review of the literatureMarie-Joëlle Mozziconacci, Nadine Carbuccia, Thomas Prebet, et al.
Leukemia Research|December 3, 2014
Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendationsValeria Santini, Thomas Prebet, Pierre Fenaux, et al.
Frontiers in Oncology|September 30, 2021
Comprehensive Clinicopathologic and Molecular Analysis of Mast Cell Leukemia With Associated Hematologic Neoplasm: A Report and In-Depth Study of 5 CasesPhilippa Li, Giulia Biancon, Timil Patel, et al.
Oncotarget|June 21, 2016
An essential pathway links FLT3-ITD, HCK and CDK6 in acute myeloid leukemiaSophie Lopez, Edwige Voisset, Julie C Tisserand, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 28, 2013
Impact of reduced-intensity conditioning allogeneic stem cell transplantation on women's fertilityEmmanuelle Assouline, Roberto Crocchiolo, Thomas Prebet, et al.
Cancer|October 20, 2010
Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine: results of a retrospective comparative studyThomas Prebet, Anne Etienne, Raynier Devillier, et al.
Bulletin Du Cancer|December 3, 2011
[Systemic learning planification for medical students during oncology clinical rotation]Anthony Gonçalves, Patrice Viens, Marine Gilabert, et al.
Pageof 10

Showing results (21-30 of 99) with videos related to

Sort By:
Pageof 10
Journal of Hematology & Oncology|October 27, 2022
Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, phase 3 trialJorge E Cortes, Tara L Lin, Kobby Asubonteng, et al.
Frontiers in Immunology|April 10, 2014
Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor ActivityAnne-Sophie Chretien, Aude Le Roy, Norbert Vey, et al.
Blood Advances|February 16, 2021
Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemiaKishan K Patel, Amer M Zeidan, Rory M Shallis, et al.
Leukemia Research|December 22, 2007
Common features of myeloproliferative disorders with t(8;9)(p12;q33) and CEP110-FGFR1 fusion: report of a new case and review of the literatureMarie-Joëlle Mozziconacci, Nadine Carbuccia, Thomas Prebet, et al.
Leukemia Research|December 3, 2014
Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendationsValeria Santini, Thomas Prebet, Pierre Fenaux, et al.
Frontiers in Oncology|September 30, 2021
Comprehensive Clinicopathologic and Molecular Analysis of Mast Cell Leukemia With Associated Hematologic Neoplasm: A Report and In-Depth Study of 5 CasesPhilippa Li, Giulia Biancon, Timil Patel, et al.
Oncotarget|June 21, 2016
An essential pathway links FLT3-ITD, HCK and CDK6 in acute myeloid leukemiaSophie Lopez, Edwige Voisset, Julie C Tisserand, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 28, 2013
Impact of reduced-intensity conditioning allogeneic stem cell transplantation on women's fertilityEmmanuelle Assouline, Roberto Crocchiolo, Thomas Prebet, et al.
Cancer|October 20, 2010
Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine: results of a retrospective comparative studyThomas Prebet, Anne Etienne, Raynier Devillier, et al.
Bulletin Du Cancer|December 3, 2011
[Systemic learning planification for medical students during oncology clinical rotation]Anthony Gonçalves, Patrice Viens, Marine Gilabert, et al.
Pageof 10